Evidence map›Paper›PMID 39945418›Full record

ArticleThe oncologist2025

The complex interplay of antibiotic use and immune checkpoint inhibition.

Lawrence W Wu, Ryan H Moy

Abstract read
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lawrence W WuDivision of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, United States.ORCID 0000-0002-8013-1275
Ryan H MoyDivision of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, United States.ORCID 0000-0002-0507-8590

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Molecular Oncology Training ProgramT32CA203703 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Katherine D Crew, DAWN HERSHMAN · 2016 to 2026
$4.1M
Defining the mechanism of inositol 1,4,5-triphosphate receptor-mediated metastatic liver colonization in colorectal cancerK08CA263304 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOY, RYAN · 2021 to 2025
$1.4M
2023 AACR-Debbie's Dream Foundation Innovation and Discovery Grant 23-80-41-MOYGastric Cancer Foundation 23-80-41-MOYNCI Molecular Oncology Training Program 5T32CA203703-09NCI NIH HHS K08 CA263304NCI NIH HHS P30 CA013696NCI NIH HHS T32 CA203703NIH HHS K08CA263304NIH/NCI Cancer Center Support P30CA013696U.S. Department of Defense HT9425-24-1-0419
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39945418
PMCPMC11822468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.